Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 19/20 | 0.82 |
| ▸ | F3 | P13726 | 19/20 | 0.82 |
| ▸ | F2 | P00734 | 19/20 | 0.82 |
| ▸ | F10 | P00742 | 19/20 | 0.82 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.82 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.82 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.82 |
| ▸ | PLG | P00747 | 10/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7661947 | 0.96 | F7 (0.77) | F7F3F2F10PRSS1 | |
| SCHEMBL7655604 | 0.93 | F7 (0.70) | F7F3F2F10PRSS1 | |
| SCHEMBL7656938 | 0.91 | F3 (1.00) | F7F3F2F10PRSS1 | |
| SCHEMBL3810484 | 0.89 | F10 (1.00) | F7F3F2F10PRSS1 | |
| SCHEMBL7651366 | 0.89 | F7 (0.67) | F7F3F2F10PRSS1 | |
| SCHEMBL7664148 | 0.89 | F7 (0.67) | F7F3F2F10PRSS1 | |
| SCHEMBL7661953 | 0.88 | F7 (0.64) | F7F3F2F10PRSS1 | |
| SCHEMBL7659439 | 0.88 | F7 (0.64) | F7F3F2F10PRSS1 | |
| SCHEMBL7664577 | 0.88 | F7 (0.82) | F7F3F2F10PRSS1 | |
| SCHEMBL7659215 | 0.87 | F7 (1.00) | F7F3F2F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6358960-B1 | FOR THERAPY OF INTRAVASCULAR COAGULATION, CORONARY THROMBOSIS, CEREBRAL INFARCTION, CEREBRAL EMBOLISM, TRANSIENT ISCHEMIC ATTACK, CEREBROVASCULAR DISORDERS, PULMONARY VASCULAR DISEASES, DEEP VENOUS THROMBOSIS, ETC. | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-03-19 | — | — | US | claimed |
| EP-1078917-A1 | AMIDINO DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-02-28 | — | — | EP | claimed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | F7 773/4885F3 183/4885F2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.